Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christiane Falge

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|June 19, 2025
[Participation and co-creation in implementation research]Anja Zscheppang, Christiane Falge, Silke Betscher, et al.
Leukemia|February 27, 2018
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IVSusanne Saussele, Rüdiger Hehlmann, Alice Fabarius, et al.
Journal of Cancer Research and Clinical Oncology|April 11, 2014
Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemiaMarkus Pfirrmann, Susanne Saussele, Andreas Hochhaus, et al.
Blood|December 8, 2009
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IVSusanne Saussele, Michael Lauseker, Alois Gratwohl, et al.
Annals of Hematology|October 29, 2013
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IVLida Kalmanti, Susanne Saussele, Michael Lauseker, et al.
Haematologica|May 20, 2014
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinibBenjamin Hanfstein, Michael Lauseker, Rüdiger Hehlmann, et al.
Blood|February 24, 2007
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemiaRüdiger Hehlmann, Ute Berger, Markus Pfirrmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IVRüdiger Hehlmann, Martin C Müller, Michael Lauseker, et al.
Blood|November 1, 2011
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVAlice Fabarius, Armin Leitner, Andreas Hochhaus, et al.
Annals of Hematology|September 20, 2015
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CMLAlice Fabarius, Lida Kalmanti, Christian T Dietz, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|June 19, 2025
[Participation and co-creation in implementation research]Anja Zscheppang, Christiane Falge, Silke Betscher, et al.
Leukemia|February 27, 2018
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IVSusanne Saussele, Rüdiger Hehlmann, Alice Fabarius, et al.
Journal of Cancer Research and Clinical Oncology|April 11, 2014
Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemiaMarkus Pfirrmann, Susanne Saussele, Andreas Hochhaus, et al.
Blood|December 8, 2009
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IVSusanne Saussele, Michael Lauseker, Alois Gratwohl, et al.
Annals of Hematology|October 29, 2013
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IVLida Kalmanti, Susanne Saussele, Michael Lauseker, et al.
Haematologica|May 20, 2014
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinibBenjamin Hanfstein, Michael Lauseker, Rüdiger Hehlmann, et al.
Blood|February 24, 2007
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemiaRüdiger Hehlmann, Ute Berger, Markus Pfirrmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IVRüdiger Hehlmann, Martin C Müller, Michael Lauseker, et al.
Blood|November 1, 2011
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVAlice Fabarius, Armin Leitner, Andreas Hochhaus, et al.
Annals of Hematology|September 20, 2015
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CMLAlice Fabarius, Lida Kalmanti, Christian T Dietz, et al.
Pageof 2